

IN THE SPECIFICATION

Please amend the specification as follows:

Please replace page 12, lines 15-16 of the originally-filed specification with the following:

A pharmaceutical composition according to any of the following 12 pharmaceutical compositions, comprising additionally a cytotoxic agent:

- (a) A pharmaceutical composition comprising a first and a second antibody molecule, or a portion thereof, having the capability to bind to different epitopes located on same or different ErbB receptor molecule types, wherein said first antibody molecule or a portion thereof, comprises binding sites that bind to a first specific epitope on the ErbB1 receptor molecule type, and said second antibody molecule comprises binding sites that bind to a second specific epitope on the same ErbB1 receptor molecule type.
- (b) A pharmaceutical composition, wherein at least said first or said second epitope on the ErbB1 receptor molecule type is located within the ErbB1 receptor binding domain.
- (c) A pharmaceutical composition, wherein said first and said second epitope on the ErbB1 receptor molecule type is located within the ErbB1 receptor binding domain.
- (d) A pharmaceutical composition, wherein said receptor binding domain is the binding domain of the natural ligand of said ErbB1 receptor molecule type.
- (e) A pharmaceutical composition, wherein the first and second antibody, or fragment thereof, binds to different epitopes within the binding domain of the natural ligand(s) of said ErbB1 receptor molecule type.
- (f) A pharmaceutical composition, wherein blocking and/or inhibition of the ErbB receptor, and induction of down-regulation of ErbB receptor-specific pathway signaling is enhanced as compared with a composition comprising a single antibody molecule which binds to said first or said second epitope on said ErbB1 receptor molecule type only.
- (g) A pharmaceutical composition, wherein the induction of cross-linking and/or dimerization of ErbB receptor molecules of the same or different specificity is enhanced as compared with a composition comprising a single antibody molecule which binds to said first or said second epitope on said ErbB1 receptor molecule type only.
- (h) A pharmaceutical composition, wherein said ErbB receptor molecules, are involved in cross-

Serial No.: 10/530,871

-2-

MERCK-2990

linking and/or dimerization, and are selected from ErbB1 and ErbB2 (Her-2).

- (i) A pharmaceutical composition, wherein said first and/or said second antibodies is a monospecific antibody.
- (j) A pharmaceutical composition, wherein the first antibody is murine, chimeric or humanized MAb 425.
- (k) A pharmaceutical composition, wherein the second antibody is murine, chimeric or humanized MAb 225.
- (l) A pharmaceutical composition, wherein said first antibody is humanized MAb 425 (h425) and said second antibody is chimeric MAb 225 (c225).

Please replace page 13, lines 15-16 of the originally-filed specification with the following:

A pharmaceutical kit according to any of the following 6 pharmaceutical kits comprising additionally a third package comprising a cytotoxic agent.

- (a) A pharmaceutical kit comprising (i) a first package comprising a first antibody molecule, or a portion thereof, which comprises binding sites that bind to a first specific epitope present on a ErbB1 receptor molecule, and (ii) a second package comprising a second antibody molecule which comprises binding sites that bind to a second different specific epitope on the same ErbB1 receptor molecule type.
- (b) A pharmaceutical kit, wherein at least said first or said second epitope on the ErbB1 receptor is located within the ErbB1 receptor binding domain.
- (c) A pharmaceutical kit, wherein said first and said second epitope on the ErbB1 receptor is located within the ErbB1 receptor binding domain.
- (d) A pharmaceutical kit, wherein at least one of said molecules binds to an epitope within the ErbB1 receptor binding domain to which the natural ligand of the receptor binds.
- (e) A pharmaceutical kit, wherein said first antibody molecule is murine, chimeric or humanized monoclonal antibody 425, and said second molecule is murine, chimeric or humanized monoclonal antibody 225.
- (f) A pharmaceutical kit comprising a first package that comprises humanized MAb 425 (h425) and a second package that comprises chimeric MAb 225 (c225).